



Gregory M. Heestand, MD

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr

MC 6507

Stanford, CA 94305

Tel (650) 498-6000 **Fax**

Bio

BIO

Dr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He currently serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He also collaborates with campus laboratories to help develop new biomarker and treatment technologies. Dr. Heestand is a member of the ECOG-ACRIN gastrointestinal committee and serves as a representative to the NCI Hepatobiliary Task Force. He is also the director of the Stanford Medical Oncology Fellowship Program.

Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.

Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read.

CLINICAL FOCUS

- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Gallbladder Cancer
- Gastrointestinal Cancers
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology

ADMINISTRATIVE APPOINTMENTS

- Oncology Fellowship Director, Stanford University, (2017- present)

PROFESSIONAL EDUCATION

- Medical Education: University of Southern California Keck School of Medicine Registrar (2004) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)
- Board Certification: Hematology, American Board of Internal Medicine (2010)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2010) CA
- Residency: University of California Davis (2007) CA
- Undergraduate, Harvard College (1998)

Research & Scholarship

CLINICAL TRIALS

- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery, Recruiting
- A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation, Not Recruiting
- Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers, Not Recruiting
- TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers, Not Recruiting

Publications

PUBLICATIONS

- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al
2021; 5 (1): 91
- **Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.** *The Journal of molecular diagnostics : JMD*
Wood-Bouwens, C. M., Haslem, D. n., Moulton, B. n., Almeda, A. F., Lee, H. n., Heestand, G. M., Nadauld, L. D., Ji, H. P.
2019
- **The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.** *Molecular cancer therapeutics*
Riviere, P. n., Fanta, P. T., Ikeda, S. n., Baumgartner, J. n., Heestand, G. M., Kurzrock, R. n.
2018; 17 (1): 297–305
- **Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.** *European journal of cancer (Oxford, England : 1990)*
Heestand, G. M., Schwaederle, M. n., Gatalica, Z. n., Arguello, D. n., Kurzrock, R. n.
2017; 83: 80–87
- **A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3** *PLOS ONE*
Shultz, D. B., Pai, J., Chiu, W., Ng, K., Hellendag, M. G., Heestand, G., Chang, D. T., Tu, D., Moore, M. J., Parulekar, W. R., Koong, A. C.
2016; 11 (1)
- **FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.** *Journal of translational medicine*
Shi, E. n., Chmielecki, J. n., Tang, C. M., Wang, K. n., Heinrich, M. C., Kang, G. n., Corless, C. L., Hong, D. n., Fero, K. E., Murphy, J. D., Fanta, P. T., Ali, S. M., De Siena, et al
2016; 14 (1): 339
- **Approach to Patients With Pancreatic Cancer Without Detectable Metastases** *JOURNAL OF CLINICAL ONCOLOGY*
Heestand, G. M., Murphy, J. D., Lowy, A. M.
2015; 33 (16): 1770-?
- **Molecular landscape of pancreatic cancer: implications for current clinical trials** *ONCOTARGET*
Heestand, G. M., Kurzrock, R.

2015; 6 (7): 4553-4561

- **A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.**
Shultz, D., Pal, J., Graber, M., Heestand, G. M., Chang, D., Parulekar, W. R., Tu, D., Moore, M. J., Koong, A.
AMER SOC CLINICAL ONCOLOGY.2014
- **A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704**
Heestand, G. M., Murphy, J., Moughan, J., Regine, W., Luo, J., Graber, M., Kunz, P. L., Fisher, G. A., Guha, C., Lin, B., Mowat, R. B., Gaur, R., Buyyounouski, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Racial Disparity in Consultation, Treatment, and the Impact on Survival in Metastatic Colorectal Cancer** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Simpson, D. R., Martinez, M. E., Gupta, S., Hattangadi-Gluth, J., Mell, L. K., Heestand, G., Fanta, P., Ramamoorthy, S., Le, Q., Murphy, J. D.
2013; 105 (23): 1814-1820
- **The Evolution of Modern Systemic Agents for Colorectal Cancer** *LOWER GASTROINTESTINAL MALIGNANCIES*
Heestand, G., Kunz, P., Fisher, G. A., Ben Josef, E., Koong, A.
2010; 1 (2): 249-60

PRESENTATIONS

- A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704 - ASCO Gastrointestinal Cancers Symposium (January 17, 2014)